Business Context and Reporting Period
Company: Incyte Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Incyte is a drug discovery and development company focused on proprietary small molecule drugs for oncology, inflammation, diabetes, and HIV. The company has transitioned from an information products business to a clinical-stage biopharmaceutical firm. As of year-end 2007, Incyte had 196 employees and maintained a pipeline with eight internally developed compounds in clinical development, four of which had advanced to Phase II trials.
Key Financial Metrics
| Metric (in millions) | 2007 | 2006 |
|---|---|---|
| Total Revenues | $34.4 | $27.6 |
| Net Loss | $(86.9) | $(74.2) |
| Loss Per Share (Basic & Diluted) | $(1.03) | $(0.89) |
| Research & Development Expenses | $104.9 | $87.6 |
| Cash, Cash Equivalents & Marketable Securities | $257.3 | $329.8 |
| Working Capital | $227.8 | $278.4 |
| Total Debt (Principal) | $421.8 | $371.1 |
| Stockholders' Deficit | $(159.5) | $(84.9) |
Note: The company reported an accumulated deficit of approximately $1.0 billion as of December 31, 2007.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 25% to $34.4 million, driven primarily by contract revenues from the Pfizer collaboration ($29.9 million in 2007 vs. $24.2 million in 2006). This included a $3.0 million milestone payment received from Pfizer in 2007.
- Increased Operating Loss: Net loss widened by $12.7 million to $86.9 million. This was primarily due to a $17.3 million increase in R&D expenses (driven by clinical pipeline advancement) and higher interest expense ($24.0 million vs. $17.9 million) due to the accretion of discounts on convertible senior notes issued in 2006.
- Cash Position: Cash and marketable securities decreased by $72.5 million to $257.3 million. While operating cash outflows increased to $92.7 million, investing activities provided $170.4 million, largely due to the sale of marketable securities and a realized gain of $8.5 million from the sale of a private investment (Velocity11).
- Debt Structure: Total debt increased due to the issuance of a $10 million convertible subordinated note to Pfizer in October 2007.
Guidance, Outlook, and Risks
Outlook and Guidance: Incyte anticipates incurring additional losses for several years as it expands drug discovery and development programs. The company does not expect to generate product sales from its drug discovery efforts for several years, if at all. Management believes current cash resources are adequate to satisfy capital needs for at least the next twelve months.
Key Clinical Developments:
- JAK Program (INCB18424): Positive interim results reported in Myelofibrosis, Rheumatoid Arthritis, and Psoriasis. Phase IIb trials planned for 2008.
- 11β-HSD1 Program (INCB13739): Positive interim results in Type 2 Diabetes; Phase IIb trial scheduled for first half of 2008.
- CCR5 Program (INCB9471): Positive Phase IIa results in HIV; Phase IIb trials planned for treatment-experienced patients.
Risks and Contingencies:
- Liquidity and Capital Needs: The company has a history of operating losses and expects to continue incurring losses. It may need to raise additional capital, which could be dilutive or require restrictive covenants.
- Debt Service: Significant debt service obligations exist, including annual interest payments of approximately $14.1 million on convertible notes through 2010. The company may not generate sufficient cash flow from operations to meet these fixed charges.
- Collaboration Dependency: A significant portion of revenue is derived from the Pfizer collaboration. Failure to achieve milestones or termination of the agreement would adversely impact revenues.
- Regulatory and Development Risk: No drug candidates have received regulatory approval. Clinical trials are expensive, time-consuming, and uncertain. Failure in clinical trials could render the pipeline valueless.
Investor Verification Checklist
- Cash Runway: Verify if the $257.3 million in cash and marketable securities is sufficient to fund the planned Phase IIb trials and debt service obligations through 2008 and beyond without additional financing.
- Pfizer Collaboration Terms: Review the specific milestones required to trigger the remaining potential $740 million in payments and royalties from Pfizer.
- Debt Conversion Risk: Assess the potential dilution from the conversion of $421.8 million in convertible notes (Senior, Subordinated, and Pfizer Notes) given the current stock price relative to conversion prices.
- Clinical Trial Timelines: Monitor the initiation and results of the planned Phase IIb trials in Myelofibrosis, Rheumatoid Arthritis, Psoriasis, and Type 2 Diabetes scheduled for 2008.
- Restructuring Obligations: Confirm the status of lease obligations for vacated facilities (Palo Alto, San Diego) which continue to generate expenses through 2011.